Litcius/Paper detail

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Puķītis, M. Horyński, Katalin Farkas, Jarosław Kierkuś, Maciej Kowalski, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Seul Gi Lee, Byong Duk Ye, Walter Reinisch

2021Gastroenterology228 citationsDOI

Topics & Concepts

MedicineClinical endpointRandomized controlled trialInfliximabUlcerative colitisInflammatory bowel diseaseInternal medicineGastroenterologyConfidence intervalCrohn's diseasePharmacokineticsRandomizationColonoscopyNuclear medicineSurgeryColorectal cancerDiseaseCancerBiosimilars and Bioanalytical MethodsInflammatory Bowel DiseaseMicroscopic Colitis
Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease | Litcius